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Cervical adenocarcinoma in situ (AIS) is a precursor to invasive
cervical adenocarcinoma (Wright et al., 2007). Adenocarcinoma accounts
for approximately 25% of cervical cancers in the United States, and the
incidence of both AIS and invasive cervical adenocarcinoma has recently
been increasing (Wright et al., 2007). AIS has challenges to managing
conservatively as the lesion may be located high in the endocervical
canal, be multicentric with “skip” lesions present, or have deep glandular
involvement. The sensitivity of cervical cytology and ECC is only approx-
imately 50% (Wolf et al., 1996), making it difﬁcult to adequately monitor
women with AIS who are managed conservatively. Furthermore, previ-
ous studies have shown that the incidence of residual AIS in hysterecto-
my specimens is approximately 52.8% with positive conization margins,
and 20% with negative conization margins. In addition, approximately
5% of patients with positive margins and 0.7% of patients with negative
margins have invasive adenocarcinoma at the time of hysterectomy
(Salani et al., 2009; Ostor et al., 2000; Bull-Phelps et al., 2007; Im et al.,
1995; McHale et al., 2001; Shin et al., 2000).
Given these challenges, the standard treatment for AIS in women
whohave completed childbearing is extrafascial hysterectomy.However,
conservative management with cervical conization with negative mar-
gins is acceptable if future fertility is desired. If conservativemanagement
is planned and themargins of the specimen are involved or endocervical
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are negative, these patients are monitored closely with a combination
of cervical cytology, HPV DNA testing, and colposcopy with endocervical
sampling (Wright et al., 2007). Long‐term follow-up is recommended in
all patients. There are a few published case reports of invasive adenocar-
cinoma occurring after hysterectomy for AIS, further illustrating the
unpredictable nature of AIS and need for close surveillance (Miller et
al., 2005; Krivak et al., 2000; Hopkins et al., 1988).
Case
A 34 year-old nulliparous woman was diagnosed with adenocarci-
noma in situ of the cervix and underwent a cold knife cone biopsy of
the cervix. The pathologic ﬁndings showed adenocarcinoma in situ
and cervical intraepithelial neoplasia 3 with negative margins. She
subsequently underwent a simple hysterectomy. Serial sectioning of
the cervix showed no invasive disease or residual AIS in the cervix. She
was followed with annual cytology, with no abnormalities noted. Four-
teen years later, she presented to her primary care physician with left
lower extremity edema. A computed tomography (CT) scan revealed
diffuse lymphadenopathy in the left inguinal, iliac, and para-aortic
areas, with the largest node measuring 4.9×2.8 cm (Fig. 1). There
were no abnormal nodes in the right iliac region. She underwent exci-
sion of the enlarged left inguinal lymphnodes, which showedmetastatic
poorly differentiated carcinoma (Fig. 2). The carcinoma was diffuselyFig. 1. Metastatic adenocarcinoma. Left inguinal mass, measuring 4.9×2.8 cm, with
biopsy consistent with metastatic poorly differentiated carcinoma.
Fig. 2. (A), (B) Adenocarcinoma in situ of the cervix. (A) Adenocarcinoma in situ of the endocervix is generally characterized at mediummagniﬁcation by the preservation of normal
glandular architecture, with an abrupt transition between normal and cytologically atypical cells. (B) At higher magniﬁcation, the features are evident, including nuclear enlarge-
ment, coarse chromatin, and stratiﬁcation of nuclei. (C) Left inguinal lymph node with metastatic poorly differentiated adenocarcinoma of the cervix. (D) Positive high-risk human
papilloma virus (HPV) DNA in situ hybridization.
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focal staining for ER and PAX8, and rare cells stained for CK 5/6. In situ
hybridization for high risk human papilloma virus (HPV) was positive.
The tumorwas felt to be consistentwithmetastatic poorly differentiated
adenocarcinoma from the cervix, vagina, or vulva. Colposcopy of the
vagina and vulva, as well as anoscopy, was unremarkable. Colonoscopy
and upper endoscopy were negative. Positron emission tomography
(PET) showed no other evidence of disease.
The patient underwent chemotherapy with six cycles of intravenous
carboplatinum and paclitaxel. Imaging at the completion of therapy
showed signiﬁcant improvement with residual small volume disease in
the left inguinal, pelvic, common iliac, and para-aortic lymph nodes. She
was therefore treated with intensity-modulated radiation therapy
(IMRT) to the left inguinal, left pelvic, and para-aortic lymph nodes with
a total dose of 50.4 Gy in 27 fractions, followed by a boost of 10 Gy in 5
fractions to PET positive nodes. Her left supraclavicular fossa was treated
prophylactically with 40 Gy given over 20 fractions. She tolerated her
treatment well with no serious adverse effects. However, a PET scan
three months following the completion of therapy showed new right in-
guinal and right pelvic lymphadenopathy, all of which was outside the
prior radiation ﬁeld. She was then treated with IMRT to the new sites of
disease in the left pelvis. Imaging three months after the completion of
therapy showed recurrent disease with several PET positive nodes in
the previously irradiated ﬁeld, as well as new peritoneal disease. The
patient is currently undergoing chemotherapy with carboplatinum and
paclitaxel.
Discussion
Recurrent invasive adenocarcinoma after deﬁnitive therapy for
AIS is a rare occurrence. This case describes the unpredictable course
of cervical AIS. There have been three other published case reports
in which invasive adenocarcinoma was diagnosed after deﬁnitive
therapy for AIS. However, these cases all describe patients in whom
either the cone specimen had positive margins or the hysterectomyspecimen showed residual disease. Miller et al. (2005) describe a patient
in whom AIS was found on a LEEP specimen with positive endocervical
margins. She subsequently underwent an abdominal hysterectomy and
bilateral salpingo-oopherectomy in whom the ﬁnal pathology showed
residual AIS, but no invasive component. She presented 28 months later
with a pelvic sidewall mass with biopsy showing invasive adenocarcino-
ma consistent with a cervical primary. Krivak et al. (2000) describe a
patient with cervical AIS with positive endocervical margins on cold
knife cone biopsy. She underwent a simple hysterectomy and bilateral
salpingo-oopherectomy with no residual disease noted. Almost two
years later, she presented with a vaginal cuff mass, with biopsy showing
invasive adenocarcinoma consistent with an endocervical primary.
Hopkins et al. (1988) reported a case of recurrent adenocarcinoma at
the vaginal cuff extending to the pelvic sidewallwith ureteral obstruction
8 years after hysterectomy in which the hysterectomy specimen
contained residual AIS after cone biopsy, but no invasive carcinoma.
Our case and the others emphasize that even in patientswho undergo
deﬁnitive therapy with hysterectomy for AIS, recurrence with invasive
adenocarcinoma may occur. The patient described in this report had
negative cone biopsy margins for cervical AIS, and an extrafascial hyster-
ectomywasperformed that showedno evidence of residual disease in the
cervix. The patient had a negative evaluation for other sources of invasive
adenocarcinoma, including negative vulvar and vaginal colposcopy,
anoscopy, colonoscopy and upper endoscopy. Furthermore, immuno-
staining suggested the tumor to be consistent withmetastasis from a cer-
vical primary. Although all pathology slides were re-reviewed, a focus of
invasive disease on the hysterectomy specimenmay not have been iden-
tiﬁed secondary to sampling issues. It is also possible that the carcinoma
represented a de novo lesion that subsequently developed.
As seen in this case and previous reports, the risk of developing
invasive disease can extend many years after deﬁnitive therapy for
AIS. It has been difﬁcult to delineate treatment recommendations
for patients based on the numerous retrospective cohorts published con-
cerning AIS management. Moreover, this case highlights the concerns
over the deﬁnitive management of adenocarcinoma in situ of the cervix
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educate patients on the symptoms of recurrence and to report them to
their physicians promptly. This case should alert physicians to the possi-
bility that AIS of the cervixmay recur several years after deﬁnitive therapy
and patients may present with metastatic disease.
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